Our in vivo findings show a promising correlation with the in vitro observations, illustrating that anti-Lair1 antibody extends survival in preclinical models of aggressive tumors, such as GBM and lung cancer, which resist PD-1 blockade. Here, PDCD1 is linked to lung carcinoma.